In an interview with Pharmacy Times, Ali A. Habib, MD, clinical professor of neurology at the University of California, Irvine, discusses what the hospitalization findings mean for patients and why they should be viewed as supportive evidence
|Videos|July 19, 2021
A Review of Data Supporting the Approval of Aducanumab for Alzheimer Disease
Findings from the 2 pivotal phase 3 trials had mixed results on cognitive benefit, although they found a positive reduction in amyloid plaque in patients' brains.
Advertisement
In an interview with Pharmacy Times, Pamela Spicer, senior analyst at Datamonitor with Informa Pharma Intelligence, reviewed the 2 pivotal phase 3 clinical trials supporting the FDA's recent approval of aducanumab. Notably, Spicer said 1 trial had a positive trend while the second trial had a negative trend, which resulted in the early cessation of both trials.
The findings had mixed results on cognitive benefit, although they found a positive reduction in amyloid plaque in patients' brains. Based on this, officials with the FDA approved the drug, Spicer said.
Advertisement
Related to this article
Victoria P. Werth, MD, discusses how litifilimab’s 52-week AMETHYST findings inform treatment expectations and timely reassessment of persistent cutaneous lupus symptoms.
In an interview with Pharmacy Times, Victoria P. Werth, MD, professor of dermatology at the University of Pennsylvania and chief of dermatology at the Philadelphia VA Medical Center, discusses why meaningful improvement extends beyond skin clearance and how response timing affects patients with difficult-to-control disease.
As psychedelic therapies advance through clinical development, pharmacists should prepare for potential roles in their safe, evidence-based integration into patient care.
The FDA approval of pritelivir offers an oral treatment for refractory HSV lesions in immunocompromised adults, with drug interactions creating an important role for pharmacists.
Weltruza, the first subcutaneous long-acting injectable (LAI) formulation of olanzapine, requires no loading doses, oral supplementation, or postinjection monitoring.
The first AHA endocarditis update in 11 years expands outpatient options, with a bigger role for pharmacists.
Investigational inhaled stem cells for COPD raise questions about lasting clinical benefit and the pharmacy controls needed to deliver a living-cell product through a nebulizer.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Pneumonic Plague: What Pharmacists Need to Know About Treatment
2
Preparing Pharmacists for Psychedelic Medicine
3
FDA Approves Pritelivir for Refractory HSV Lesions in Immunocompromised Adults
4
FDA Approves First Once-Monthly Subcutaneous Olanzapine LAI for Adults With Schizophrenia
5